Editorial: Stem cell oversight board is flying blind
By Sacramento Bee,
Sacramento Bee
| 09. 18. 2005
Robert Klein II, the self-appointed czar of California's stem cell institute, has created a completely unworkable system for dispensing $3 billion in taxpayer-funded research grants.
In fact, it is hard to imagine a system that is more convoluted and opaque than what Klein has created. Its shortcomings were on full display at a Sept. 9 meeting of the institute's oversight board here in Sacramento.
At the meeting, the 29-person board (with a few members absent) labored to decide which universities and research entities should receive the institute's first training grants, totalling about $13 million per year.
During the meeting, the distinguished scientists on the panel resembled ballerinas in Kurt Vonnegut's story, "Harrison Bergeron," who tried to dance with bag weights. The scientists didn't have the information they needed to make knowledgable decisions, and many seemed frustrated because of it.
Here's how the system works:
An applicant - a California researcher or university - applies to the stem cell institute for a grant. That application is reviewed by a working group of out-of-state scientists and eight patient advocates who serve on...
Related Articles
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Aleks Krotoski, The Guardian | 09.28.2025
Imagine you’re the leader of one of the most powerful nations in the world. You have everything you could want at your disposal: power, influence, money. But, the problem is, your time at the top is fleeting. I’m not...
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...